Request a copy

Full Text

• Ranieri VM, Thompson BT, Barie PS, et al: Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 2012; 366:2055-2064
• Bone RC, Fisher CJ Jr, Clemmer TP, et al: Sepsis syndrome: A valid clinical entity. Methylprednisolone Severe Sepsis Study Group. Crit Care Med 1989; 17:389-393
• Ziegler EJ, Fisher CJ Jr, Sprung CL, et al: Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. N Engl J Med 1991; 324:429-436
• Cometta A, Baumgartner JD, Glauser MP: Polyclonal intravenous immune globulin for prevention and treatment of infections in critically ill patients. Clin Exp Immunol 1994; 97(Suppl 1):69-72
• Bernard GR, Vincent JL, Laterre PF, et al: Effcacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709
• Panacek EA, Marshall JC, Albertson TE, et al: Effcacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels. Crit Care Med 2004; 32:2173-2182
• Annane D, Sébille V, Charpentier C, et al: Effect of treatment with low doses of hydrocortisone and fudrocortisone on mortality in patients with septic shock. JAMA 2002; 288:862-871
• Abraham E, Laterre P F, Garg R, et al: Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005; 353:1332-1341
• Sprung CL, Annane D, Keh D, et al: Hydrocortisone therapy for patients with septic shock. N Engl J Med 2008; 358:111-124
• Hotchkiss RS, Opal S: Immunotherapy for sepsis-A new approach against an ancient foe. N Engl J Med 2010; 363:87-89
• Tracey KJ, Fong Y, Hesse DG, et al: Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 1987; 330:662-664
• Dinarello CA: Biologic basis for interleukin-1 in disease. Blood 1996; 87:2095-2147
• Sánchez-Cantú L, Rode HN, Yun TJ, et al: Tumor necrosis factor alone does not explain the lethal effect of lipopolysaccharide. Arch Surg 1991; 126:231-235
• Tetta C, Gianotti L, Cavaillon J-M, et al: Continuous plasmafltration coupled with sorbent adsorption in a rabbit model of endotoxic shock. Crit Care Med 2000; 28:1526-1533
• Bagby GJ, Plessala KJ, Wilson LA, et al: Divergent effcacy of antibody to tumor necrosis factor-alpha in intravascular and peritonitis models of sepsis. J Infect Dis 1991; 163:83-88
• Zakharova M, Ziegler HK: Paradoxical anti-infammatory actions of TNF-alpha: Inhibition of IL-12 and IL-23 via TNF receptor 1 in macro-phages and dendritic cells. J Immunol 2005; 175:5024-5033
• Noti M, Corazza N, Mueller C, et al: TNF suppresses acute intestinal infammation by inducing local glucocorticoid synthesis. J Exp Med 2010; 207:1057-1066
• Bannerman DD, Goldblum SE: Direct effects of endotoxin on the endo-thelium: barrier function and injury. Lab Invest 1999; 79:1181-1199
• Galle M, Jin S, Bogaert P, et al: The Pseudomonas aeruginosa type III secretion system has an exotoxin S/T/Y independent pathogenic role during acute lung infection. PLoS One 2012; 7:e41547
• Tamion F, Richard V, Renet S, et al: Protective effects of heme-oxygenase expression against endotoxic shock: Inhibition of tumor necrosis factor-alpha and augmentation of interleukin-10. J Trauma 2006; 61:1078-1084
• Han X, Fink MP, Uchiyama T, et al: Increased iNOS activity is essential for pulmonary epithelial tight junction dysfunction in endo-toxemic mice. Am J Physiol Lung Cell Mol Physiol 2004; 286: L259-L267
• Han X, Fink MP, Uchiyama T, et al: Increased iNOS activity is essential for hepatic epithelial tight junction dysfunction in endotoxemic mice. Am J Physiol Gastrointest Liver Physiol 2004; 286: G126-G136